Hong Kong-listed Brii Biosciences Limited conducted an on-market repurchase of 78,000 ordinary shares on 23 October 2026 under its existing share-buyback mandate approved on 16 June 2026.
The shares were acquired on the Stock Exchange of Hong Kong at prices ranging between HKD 0.88 and HKD 0.915, with a volume-weighted average cost of HKD 0.8942 per share. The total cash consideration amounted to HKD 0.07 million.
Following the transaction: • Issued shares outstanding (excluding treasury shares) fell by 78,000, or 0.0108%, to 721.58 million. • Treasury shares increased to 13.74 million, equivalent to roughly 1.87% of the company’s total issued share capital of 735.32 million shares. • Total issued share capital remained unchanged as the repurchased shares are being held in treasury and have not been cancelled.
Cumulatively, Brii Biosciences has repurchased 1.02 million shares since receiving authority to buy back up to 72.19 million shares, utilising 0.14% of the mandate and leaving capacity for a further 71.17 million shares.
Under Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, ending on 22 November 2026. The company confirmed that all repurchases complied with Main Board Rule 10.06 and that no material changes have been made to the explanatory statement filed with the Exchange.
Comments